RAZOR: RAD001 and ZOledronic acid in Renal cell carcinoma patients with bone metastases
– a randomised phase II trial CTNZ_09_01
Registration number:
|
ACTRN12609000980235 |
Ethics number:
|
MEC/09/12/134 |
This is a multi centre, randomised phase II, open parallel group study. The main
purpose of this study is to find out whether giving the two treatments (RAD001 plus
zoledronic acid) together is more effective than RAD001 alone in controlling the
bone secondaries in patients with renal cell carcinoma.
If you would like more information please contact:
Progress
This trial is open to recruitment.
Results
None to date.
Centres involved
- Auckland (lead centre)
- Palmerston North
